Boehringer Ingelheim has made its first investment from its corporate venturing fund launched in March in Okairòs, a Switzerland-based drug development company, which has raised €16m ($20.5m) in its series B round.
The financing was led by venture capital firm Versant Ventures and joined by the €100m Boehringer Ingelheim Venture Fund. All existing investors from Okairòs’ €7.2m series A round in 2007 reinvested. The A round was led by VCs Life Science Partners and BioMedPartners which were joined by local…
